Illustration: Gabriella Turrisi/Axios
Attovia Therapeutics, a clinical-stage biopharma company developing treatments for autoimmune diseases, closed a $90 million Series C round.
Why it matters: The financing, announced today, gives Attovia a "multi-year" runway to further develop its pipeline of five therapeutic candidates.
